Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

The prognosis for patients with locally advanced or metastatic breast cancer (mBC) remains poor, with a median survival of 2–4 years. About 10% of newly diagnosed breast cancer patients present with metastatic disease, and 30%–50% of those diagnosed at earlier stages will subsequently progress to mB...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Onco Targets Ther
Hauptverfasser: Cazzaniga, Marina Elena, Biganzoli, Laura, Cortesi, Laura, De Placido, Sabino, Donadio, Michela, Fabi, Alessandra, Ferro, Antonella, Generali, Daniele, Lorusso, Vito, Milani, Andrea, Montagna, Emilia, Munzone, Elisabetta, Orlando, Laura, Pizzuti, Laura, Simoncini, Edda, Zamagni, Claudio, Pappagallo, Giovanni L
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove Medical Press 2019
Schlagworte:
Expert Opinion
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6485034/
https://ncbi.nlm.nih.gov/pubmed/31114242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S189163
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge